Striving to achieve safe, permanent treatment discontinuation in chronic myeloid leukemia-Reference-Cited by-同舟云学术

Striving to achieve safe, permanent treatment discontinuation in chronic myeloid leukemia

Published:2013-11 Issue:11 Volume:37 Page:1395-1403
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Mauro Michael J.

Funder

Bristol-Myers Squibb

Ariad Pharmaceuticals

Novartis Pharmaceuticals Corporation

Novartis

Pfizer

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference81 articles.

1. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia;Hochhaus;Leukemia,2009

2. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O’Brien;N Engl J Med,2003

3. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia;Saglio;N Engl J Med,2010

4. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia;Kantarjian;N Engl J Med,2010

5. Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION);Kantarjian;Blood,2011

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monitoring and Analysis of Chinese Chronic Myeloid Leukemia Patients Who Have Stopped Tyrosine Kinase Inhibitor Therapy;Current Medical Science;2019-04

2. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia;BMC Cancer;2018-04-02

3. Present and future of molecular monitoring in chronic myeloid leukaemia;British Journal of Haematology;2016-03-07

4. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia patients – worldwide battlefield;Neoplasma;2015

5. Real-Time Analysis of Imatinib- and Dasatinib-Induced Effects on Chronic Myelogenous Leukemia Cell Interaction with Fibronectin;PLoS ONE;2014-09-08